CG Oncology Q3 net loss widens 30% year over year to $56.89 million

• CG Oncology’s third-quarter 2026 net loss widened 30% year-over-year to $56.89 million, while total revenues fell to $1.6 million.
• R&D expenses rose 41% year-over-year to $39.22 million due to higher clinical trial and compensation costs.
• Cash, cash equivalents and marketable securities totaled $984.5 million at September 30, 2026, sufficient to fund operations through 2029.
• PIVOT-006 topline data expected November 2026; 12-month BOND-003 Cohort P and CORE-008 Cohort CX data expected December 2026.
• Completion of the BLA submission for cretostimogene in BCG-unresponsive NMIBC with CIS, with or without papillary disease, is anticipated Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060815PRIMZONEFULLFEED9871914) on November 06, 2026, and is solely responsible for the information contained therein.